Inhibition of Ceramide Synthesis Ameliorates Glucocorticoid-, Saturated-Fat-, and Obesity-Induced Insulin Resistance

Cell Metabolism

Volumn 5, Issue 3, 2007, Pages 167-179

  Holland, William L ^a   Brozinick, Joseph T ^b   Wang, Li Ping ^a   Hawkins, Eric D ^b   Sargent, Katherine M ^a   Liu, Yanqi ^a   Narra, Krishna ^a   Hoehn, Kyle L ^a   Knotts, Trina A ^a   Siesky, Angela ^b   Nelson, Don H ^a   Karathanasis, Sotirios K ^b   Fontenot, Greg K ^c   Birnbaum, Morris J ^d   Summers, Scott A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c LEXICON PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

HUMDISEASE

Indexed keywords

CERAMIDE; GLUCOCORTICOID; INSULIN; SATURATED FATTY ACID; SPHINGOLIPID; UNSATURATED FATTY ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; EMBRYO; GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPOGENESIS; MALE; METABOLIC INHIBITION; METABOLIC STRESS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; RAT; RODENT;

ANIMALS; CERAMIDES; DIABETES MELLITUS, TYPE 2; FATS, UNSATURATED; FATTY ACIDS; GLUCOCORTICOIDS; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MICE; MICE, KNOCKOUT; OBESITY; OXIDOREDUCTASES; RATS; RATS, SPRAGUE-DAWLEY; SPHINGOLIPIDS;

RODENTIA;

EID: 33847332202     PISSN: 15504131     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cmet.2007.01.002     Document Type: Article

References (49)

1. Adams II J.M., Pratipanawatr T., Berria R., Wang E., DeFronzo R.A., Sullards M.C., and Mandarino L.J. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53 (2004) 25-31
2. Boden G., and Shulman G.I. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur. J. Clin. Invest. 32 Suppl 3 (2002) 14-23
3. Brozinick Jr. J.T., and Birnbaum M.J. Insulin, but not contraction, activates Akt/PKB in isolated rat skeletal muscle. J. Biol. Chem. 273 (1998) 14679-14682
4. Chavez J.A., and Summers S.A. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch. Biochem. Biophys. 419 (2003) 101-109
5. Chavez J.A., Knotts T.A., Wang L.P., Li G., Dobrowsky R.T., Florant G.L., and Summers S.A. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J. Biol. Chem. 13 (2003) 10297-10303
6. Chavez J.A., Holland W.L., Bar J., Sandhoff K., and Summers S.A. Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling. J. Biol. Chem. 280 (2005) 20148-20153
7. Dobrzyn A., Zendzian-Piotrowska M., and Gorski J. Effect of endurance training on the sphingomyelin-signalling pathway activity in the skeletal muscles of the rat. J. Physiol. Pharmacol. 55 (2004) 305-313
8. Gaster M., Rustan A.C., and Beck-Nielsen H. Differential utilization of saturated palmitate and unsaturated oleate: evidence from cultured myotubes. Diabetes 54 (2005) 648-656
9. Gorska M., Dobrzyn A., Zendzian-Piotrowska M., and Gorski J. Effect of streptozotocin-diabetes on the functioning of the sphingomyelin-signalling pathway in skeletal muscles of the rat. Horm. Metab. Res. 36 (2004) 14-21
10. Hajduch E., Balendran A., Batty I.H., Litherland G.J., Blair A.S., Downes C.P., and Hundal H.S. Ceramide impairs the insulin-dependent membrane recruitment of protein kinase B leading to a loss in downstream signalling in L6 skeletal muscle cells. Diabetologia 44 (2001) 173-183
11. Hannun Y.A., and Obeid L.M. The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J. Biol. Chem. 277 (2002) 25847-25850
12. Helge J.W., Dobrzyn A., Saltin B., and Gorski J. Exercise and training effects on ceramide metabolism in human skeletal muscle. Exp. Physiol. 89 (2004) 119-127
13. Hermanowski-Vosatka A., Balkovec J.M., Cheng K., Chen H.Y., Hernandez M., Koo G.C., Le Grand C.B., Li Z., Metzger J.M., Mundt S.S., et al. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. 202 (2005) 517-527
14. Hojjati M., Li Z., Zhou H., Tang S., Huan C., Ooi E., Lu S., and Jiang X.C. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J. Biol. Chem. 280 (2005) 10284-10289 10.1074/jbc.M412348200 Published online December 6, 2004
15. Hotamisligil G.S. Inflammatory pathways and insulin action. Int. J. Obes. Relat. Metab. Disord. 27 Suppl 3 (2003) S53-S55
16. Itani S.I., Ruderman N.B., Schmieder F., and Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 51 (2002) 2005-2011
17. Kim J.K., Kim Y.J., Fillmore J.J., Chen Y., Moore I., Lee J., Yuan M., Li Z.W., Karin M., Perret P., et al. Prevention of fat-induced insulin resistance by salicylate. J. Clin. Invest. 108 (2001) 437-446
18. Kim J.K., Fillmore J.J., Sunshine M.J., Albrecht B., Higashimori T., Kim D.W., Liu Z.X., Soos T.J., Cline G.W., O'Brien W.R., et al. PKC-theta knockout mice are protected from fat-induced insulin resistance. J. Clin. Invest. 114 (2004) 823-827
19. Kim Y.B., Shulman G.I., and Kahn B.B. Fatty acid infusion selectively impairs insulin action on Akt1 and protein kinase C lambda /zeta but not on glycogen synthase kinase-3. J. Biol. Chem. 277 (2002) 32915-32922
20. Kotelevtsev Y., Holmes M.C., Burchell A., Houston P.M., Schmoll D., Jamieson P., Best R., Brown R., Edwards C.R., Seckl J.R., et al. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. USA 94 (1997) 14924-14929
21. Kotelevtsev Y., Brown R.W., Fleming S., Kenyon C., Edwards C.R., Seckl J.R., and Mullins J.J. Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. J. Clin. Invest. 103 (1999) 683-689
22. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., and Flier J.S. A transgenic model of visceral obesity and the metabolic syndrome. Science 294 (2001) 2166-2170
23. Masuzaki H., Yamamoto H., Kenyon C.J., Elmquist J.K., Morton N.M., Paterson J.M., Shinyama H., Sharp M.G., Fleming S., Mullins J.J., et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 112 (2003) 83-90
24. McGarry J.D. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51 (2002) 7-18
25. Merrill Jr. A.H. De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J. Biol. Chem. 277 (2002) 25843-25846
26. Olshansky S.J., Passaro D.J., Hershow R.C., Layden J., Carnes B.A., Brody J., Hayflick L., Butler R.N., Allison D.B., and Ludwig D.S. A potential decline in life expectancy in the United States in the 21st century. N. Engl. J. Med. 352 (2005) 1138-1145
27. Pagliassotti M.J., Kang J., Thresher J.S., Sung C.K., and Bizeau M.E. Elevated basal PI 3-kinase activity and reduced insulin signaling in sucrose-induced hepatic insulin resistance. Am. J. Physiol. Endocrinol. Metab. 282 (2002) E170-E176
28. Park T.S., Panek R.L., Mueller S.B., Hanselman J.C., Rosebury W.S., Robertson A.W., Kindt E.K., Homan R., Karathanasis S.K., and Rekhter M.D. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 110 (2004) 3465-3471
29. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29 (2001) e45
30. Powell D.J., Hajduch E., Kular G., and Hundal H.S. Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol. Cell. Biol. 23 (2003) 7794-7808
31. Powell D.J., Turban S., Gray A., Hajduch E., and Hundal H.S. Intracellular ceramide synthesis and protein kinase Czeta activation play an essential role in palmitate-induced insulin resistance in rat L6 skeletal muscle cells. Biochem. J. 382 (2004) 619-629
32. Reaven G.M. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu. Rev. Nutr. 25 (2005) 391-406
33. Riebeling C., Allegood J.C., Wang E., Merrill Jr. A.H., and Futerman A.H. Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors. J. Biol. Chem. 278 (2003) 43452-43459
34. Rivellese A.A., and Lilli S. Quality of dietary fatty acids, insulin sensitivity and type 2 diabetes. Biomed. Pharmacother. 57 (2003) 84-87
35. Schmitz-Peiffer C. Signalling aspects of insulin resistance in skeletal muscle: mechanisms induced by lipid oversupply. Cell. Signal. 12 (2000) 583-594
36. Stein D.T., Stevenson B.E., Chester M.W., Basit M., Daniels M.B., Turley S.D., and McGarry J.D. The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J. Clin. Invest. 100 (1997) 398-403
37. Straczkowski M., Kowalska I., Nikolajuk A., Dzienis-Straczkowska S., Kinalska I., Baranowski M., Zendzian-Piotrowska M., Brzezinska Z., and Gorski J. Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle. Diabetes 53 (2004) 1215-1221
38. Stratford S., DeWald D.B., and Summers S.A. Ceramide dissociates 3′-phosphoinositide production from pleckstrin homology domain translocation. Biochem. J. 354 (2001) 359-368
39. Stratford S., Hoehn K.L., Liu F., and Summers S.A. Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J. Biol. Chem. 279 (2004) 36608-36615
40. Summers S.A., and Nelson D.H. A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome. Diabetes 54 (2005) 591-602
41. Summers S.A., Garza L.A., Zhou H., and Birnbaum M.J. Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol. Cell. Biol. 18 (1998) 5457-5464
42. Teruel T., Hernandez R., and Lorenzo M. Ceramide mediates insulin resistance by tumor necrosis factor-alpha in brown adipocytes by maintaining Akt in an inactive dephosphorylated state. Diabetes 50 (2001) 2563-2571
43. Turinsky J., O'Sullivan D.M., and Bayly B.P. 1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. J. Biol. Chem. 265 (1990) 16880-16885
44. Wakelam M.J. Diacylglycerol-when is it an intracellular messenger?. Biochim. Biophys. Acta 1436 (1998) 117-126
45. Wang C.-N., O'Brien L., and Brindley D.N. Effects of cell-permeable ceramides and tumor necrosis factor-α on insulin signaling and glucose uptake in 3T3-L1 adipocytes. Diabetes 47 (1998) 24-31
46. Wang L.P., and Summers S.A. Measuring insulin-stimulated phosphatidyl-inositol 3-kinase activity. Methods Mol. Med. 83 (2003) 127-136
47. Ye J.M., Doyle P.J., Iglesias M.A., Watson D.G., Cooney G.J., and Kraegen E.W. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 50 (2001) 411-417
48. Yu C., Chen Y., Cline G.W., Zhang D., Zong H., Wang Y., Bergeron R., Kim J.K., Cushman S.W., Cooney G.J., et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277 (2002) 50230-50236
49. Zambrowicz B.P., Friedrich G.A., Buxton E.C., Lilleberg S.L., Person C., and Sands A.T. Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells. Nature 392 (1998) 608-611